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Abstract
Metabolic alkalosis is a disorder where the primary defect, an increase in plasma bicar-
bonate concentration, leads to an increase in systemic pH. Here we review the causes 
of metabolic alkalosis with an emphasis on the inherited causes, namely Gitelman syn-
drome and Bartter syndrome and syndromes which mimic them. We detail the impor-
tance of understanding the kidney pathophysiology and molecular genetics in order to 
distinguish these syndromes from acquired causes. In particular we discuss the tubular 
transport of salt in the thick ascending limb of the loop of Henle, the distal convoluted 
tubule and the collecting duct. The effects of salt wasting, namely an increase in the renin-
angiotensin-aldosterone axis are discussed in order to explain the biochemical pheno-
types and targeted treatment approaches to these conditions.
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1. Introduction
Metabolic alkalosis is a disorder where the primary defect, an increase in plasma bicarbon-
ate concentration, leads to an increase in systemic pH. Various mechanisms underpin the 
pathophysiology of metabolic alkalosis, which is defined by an arterial bicarbonate concen-
tration of over 28 mmol/L or a venous total carbon dioxide concentration of greater than 
30 mmol/L. The body compensates for alkali retention and subsequent elevated arterial pH by 
inducing respiratory hypoventilation resulting in an accompanying rise in PaCO
2
. Normally 
the kidney, which has a protective mechanism against the development of significant 
increases in bicarbonate, will excrete excess alkali to restore the body to its homeostatic pH, 
but certain factors can impair this ability resulting in a sustained alkalotic state. Here we will 
review the pathophysiological mechanisms and clinical settings in which metabolic alkalosis 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
may occur [1–4] and give an overview of the causes of the inherited forms of metabolic alka-
losis. The importance of defining a molecular genetic cause of metabolic alkalosis is reviewed 
alongside the common mimics of some of the inherited metabolic alkalosis syndromes.
2. Pathophysiology of metabolic alkalosis
The following mechanisms result in the elevation of serum bicarbonate; excessive loss of 
hydrogen ions by the kidney or via the GI tract, intracellular shift of hydrogen ions, retention 
of exogenous bicarbonate ions or volume contraction around a constant supply of extracel-
lular bicarbonate (contraction alkalosis) [5].
As water dissociates in the body to hydrogen and hydroxyl ions, the hydroxyl ions combine 
with carbon dioxide, resulting in bicarbonate, as hydrogen ions are removed from extracellular 
fluid. Hydrogen ion removal in the kidney and GI tract is accompanied by loss of potassium 
and chloride so hypokalaemia and hypochloraemia often coexist with metabolic alkalosis.
Ability to excrete excess bicarbonate depends on the normal function of nephrons within the 
kidneys. The kidney therefore is implicated in the pathophysiology of most forms of meta-
bolic alkalosis. The following scenarios result in a degree of impairment of this important 
mechanism: hypovolaemia, reduced glomerular filtration rate (GFR), reduced effective arte-
rial volume, hypokalaemia, hypochloraemia or hyperaldosteronism.
2.1. Volume depletion
Both reduced extracellular volume and arterial pressure will reduce GFR and thus activate 
the renin-angiotensin-aldosterone and sympathetic nervous system. Decreased GFR reduces 
bicarbonate filtration by the kidney and angiotensin and sympathetic activation increases 
bicarbonate reabsorption and generation in addition to sodium reabsorption in the tubule. 
This is done in the following ways:
• Angiotensin-2 stimulates apical sodium-hydrogen exchange and basolateral sodium bicarbon-
ate co-transport in the proximal tubule. This increases bicarbonate and sodium reabsorption.
• In the apical membrane of alpha-intercalated cells of the collecting duct angiotensin-2 and 
aldosterone increase H+-ATPase pump activity resulting in increased urinary excretion of 
hydrogen ions. This results in increased intracellular bicarbonate generation which exits 
the cell in exchange for chloride via the basolateral membrane.
• Increases in aldosterone stimulate the apically located ENaC channel in the principal cells, 
which generates an electronegative potential in the tubular lumen. This enhances hydro-
gen and potassium ion excretion.
2.2. Sodium intake
A low sodium chloride diet will increase the bicarbonate reabsorption in the kidney enough 
to elevate serum pH although the reverse is not true with a high salt diet even though this will 
encourage the kidney to excrete sodium bicarbonate.
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2.3. Chloride depletion
Chloride depletion secondary to vomiting or nasogastric suction leads to a metabolic alkalo-
sis. Chloride depletion metabolic alkalosis causes concomitant potassium depletion through 
renal loss of potassium. A less severe chloride depletion metabolic alkalosis is seen with the 
use of thiazide and loop diuretics.
2.4. Hypokalaemia
Hypokalaemia causes alkalosis by moving hydrogen ions into the intracellular space in 
exchange for extracellular movement of potassium and hypokalaemia maintains an alkalosis 
by increasing renal bicarbonate reabsorption. Hypokalaemia (and aldosterone) stimulates the 
distal Na+-K+-ATPase and H+-ATPase pumps in the apical membrane of alpha-intercalated 
cells to reabsorb potassium and secrete hydrogen and subsequently maintain alkalosis. 
Hypokalaemia also causes extracellular movement of potassium in exchange for intracellular 
movement of sodium and hydrogen which generates extracellular bicarbonate although co-
existent intracellular acidosis. This intracellular acidosis stimulates renal bicarbonate reab-
sorption, hydrogen secretion and ammonium synthesis and excretion.
2.5. Increased aldosterone
Hyperaldosteronism in addition to increased distal tubule sodium delivery results in sodium 
reabsorption and hydrogen and potassium ion secretion. Any hyper-reninaemic state which 
will result in an increase in aldosterone production will have the same effects.
2.6. Volume contraction and beta-intercalated cells
Distal tubule chloride delivery is essential for the beta-intercalated cell to secrete bicarbonate as 
this occurs by an apical anion exchange protein called Pendrin (Figure 3). As volume contraction 
reduces distal chloride delivery, bicarbonate secretion will reduce as will chloride reabsorption. 
Urine pH becomes acidic with little chloride, sodium and potassium, so beta-intercalated cells 
are blunted from excreting bicarbonate and correcting the metabolic alkalosis [1–4].
3. Causes of metabolic alkalosis
3.1. Diuretics
Loop diuretics (Furosemide, Bumetanide, Torsemide) inhibit the apical Na+–K+–2Cl− co- 
transporter in the thick ascending limb of the loop of Henle where 20–25% of sodium is typi-
cally reabsorbed. Metabolic alkalosis occurs in several ways [6, 7]:
• Increased distal sodium delivery results in stimulation of the aldosterone sensitive sodium 
channel (ENaC) which increases hydrogen/potassium ion excretion.
• Hypochloraemia will also contribute to the metabolic alkalosis.
The same principle also applies to other diuretics such as thiazides.
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3.2. Post-hypercapnia
Patients who are chronic CO
2
 retainers typically develop a compensatory metabolic alkalosis 
due to renal bicarbonate retention. Once the hypercapnia is reversed with ventilatory sup-
port, the renal bicarbonate retention takes longer to correct and these patients usually have a 
chronically elevated bicarbonate [8].
3.3. Non-reabsorbable anion delivery
Antibiotics particularly Beta-lactams act as non-reabsorbable anions in the renal tubule which 
therefore promotes potassium and hydrogen excretion which results in metabolic alkalosis [9].
3.4. Inherited salt wasting alkaloses
Bartter and Gitelman syndromes are both autosomal recessive inherited disorders which 
result in characteristic features due to a hereditary dysfunction in a tubular salt handling [10]. 
Both result in hypokalaemia, metabolic alkalosis, hyper-reninaemia and hyperaldosteronism 
with low blood pressure. The prevalence of Gitelman syndrome is about 1 in 40,000 compared 
with Bartter syndrome, which has a prevalence of 1 in 1,000,000. Bartter syndrome is more 
severe and may cause perinatal death due to salt wasting crises. The clinical phenotype that 
is seen with Gitelman syndrome mimics the chronic ingestion of a thiazide diuretic and that 
of Bartter syndrome mimics a chronic loop diuretic effect (Table 1). Bartter and Gitelman 
syndrome carriers (heterozygous for a mutation in causative gene) typically have lower blood 
pressure than that of the general population and may have mild biochemical phenotypes and 
some clinical symptoms.
Bartter syndrome results from a primary defect in sodium chloride reabsorption in the thick 
ascending limb of the loop of Henle (Figure 1). Salt (sodium) wasting results in volume 
depletion which activates juxtaglomerular secretion of renin and subsequent juxtaglomerular 
hyperplasia and hyperaldosteronism. Volume depletion and increased distal tubular sodium 
delivery result in tubular potassium and hydrogen secretion in the urine [11, 12]. Paracellular 
reabsorption of calcium and magnesium in the thick ascending limb of the loop of Henle is 
driven by sodium chloride reabsorption in this nephron segment. Reduced sodium absorp-
tion here results in hypercalciuria and hypomagnesaemia [13].
To date, there are five types of Bartter syndrome based on different genetic defects (Figure 1) 
with slightly variable phenotypic presentations [14].
Type 1: mutations SLC12A1 which encodes the apically located Na-K-2Cl (NKCC2) result in a 
severe phenotype which can cause maternal polyhydramnios and prematurity. Subsequently, 
few survive infancy due to extreme salt wasting resulting in significant hypokalaemia, meta-
bolic alkalosis, polyuria and hypercalciuria.
Type 2: mutations in KCNJ1, which encodes the apical potassium channel ROMK essential for 
potassium recirculation in the thick ascending limb of the loop of Henle results in salt-wasting 
alkalosis. Nephrocalcinosis is common which often results in later renal dysfunction and, in 
some cases, end stage renal failure [15].
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Type 3: mutations in CLCNKB result in loss of function of the basolateral chloride channel 
ClC-Kb which is historically described as the ‘classical’ form of Bartter syndrome. This form 
is less severe and may present later in childhood. Co-expression of ClC-Ka results in a less 
severe phenotype. Some patients with CLCNKB mutations have a Gitelman syndrome phe-
notype with hypocalciuria and thiazide non-responsiveness because ClC-Kb is also involved 
with chloride reabsorption along the distal convoluted tubule in addition to the thick ascend-
ing limb of the loop of Henle. Late renal impairment can feature in this form of Bartter syn-
drome mainly due to nephrocalcinosis and the adverse effects of NSAIDS (used as treatment 
for the condition) [16].
Bartter syndrome Gitelman syndrome
Site of defect NKCC2, ROMK, CLC-KB, CLC-KA 
and CaSR in the thick ascending 
limb of the loop of Henle
Apical sodium chloride co-transporter (NCCT) 
at the distal convoluted tubule
Metabolic alkalosis Present Present
Hypokalaemia Present Present
Hypocalcaemia Rare (seen in Type 5 Bartter 
syndrome)
Absent
Hypomagnesaemia Occasionally present Present
Urine chloride and sodium 
excretion
High Normal/high
Urine potassium excretion Normal/high High
Urine calcium excretion Normal/high Low
Urinary concentrating ability Impaired Normal
Urine prostaglandin excretion High Normal
Hyper-reninaemic 
Hyperaldosteronism
Present Present
Age at presentation Antenatal/neonatal periods Childhood/adolescence/adult
Polyhydramnios Common Absent
Failure to thrive Typically present Absent
Growth retardation Typically present Rarely present
Polyuria and polydipsia Present Absent
Sensorineural deafness Present in Type 4 Bartter syndrome Absent
Chondrocalcinosis Absent Occasionally present
Nephrocalcinosis Present in Type 1 and Type 2 
Bartter syndrome
Absent
Muscle weakness/tetany Occasionally present Present
Table 1. Differences between Bartter and Gitelman syndrome.
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Type 4: two mechanisms underlie type 4 Bartter syndrome. Both defects cause severe disease 
in the antenatal period and present with co-existent congenital deafness. Progressive renal 
failure is more common but nephrocalcinosis is less commonly seen. Type 4A is a consequence 
of a defect in the Barttin subunit that is essential to the function of both the chloride channels 
ClC-Ka and ClC-Kb which are present in both the renal tubule and the stria vascularis of the 
cochlear (inner ear). Bartter type 4b involves a second mechanism whereby digenic mutations 
affect both chloride channels (CLCNKA and CLCNKB) [17].
Type 5: this form of Bartter syndrome is due to a gain of function mutation in CASR encoding 
the calcium sensing receptor (CaSR). This is also termed autosomal dominant hypocalcaemia. 
This condition results in a low serum calcium as a result of downward ‘resetting’ of the para-
thyroid gland and hypocalcaemia subsequently inhibits parathyroid hormone release. The 
gain of function mutation in CaSR additionally regulates paracellular calcium transport in the 
thick ascending limb of the loop of Henle. CaSR over-activation reduces ROMK expression in 
addition to blunting Na+–K+–2Cl− co-transporter expression resulting in renal sodium chloride 
wasting. Calcium and magnesium reabsorption via paracellular channels is inhibited due to 
lack of electrochemical gradient to drive paracellular reabsorption. This Bartter syndrome 
subtype is unique due to the presence of hypocalcaemia and an autosomal dominant inheri-
tance pattern and has a milder phenotype (with much less alkalosis) and with later onset [18].
A transient form of Bartter syndrome exists as an X-linked pattern of inheritance which mani-
fests in the antenatal period. This form presents with severe polyhydramnios and prematurity 
Figure 1. The thick ascending loop of Henle and the transporters and channels associated with tubulopathies.
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if the foetus survives to this stage. Severe salt wasting results in foetal polyuria and those that 
survive to birth have spontaneous resolution in symptoms over the first few months/years of 
life. Mutations in MAGED2, which encodes melanoma-associated antigen D2, underlie this 
condition. The gene is thought to affect the antenatal expression and function of NKCC2 and 
NCC via adenylate cyclase, a cytoplasmic heat-shock protein and cyclic AMP [19].
The apically expressed furosemide sensitive co-transporter/sodium potassium chloride co-
transporter (NKCC2) is shown. Mutations in Type 1 Bartter syndrome are associated with 
dysfunction in this channel, leading to salt wasting. Mutations in the apical potassium chan-
nel ROMK cause Type 2 Bartter syndrome. ROMK is essential for potassium recycling back to 
the lumen of the tubule in this nephron segment. Mutations in CLCNKB encoding the basolat-
eral chloride channel ClC-Kb cause type 3 Bartter syndrome (as well as causing phenotypes 
similar to Gitelman syndrome). Type 4 Bartter syndrome is due to mutations in BSND which 
acts as a subunit for both ClC-Kb and ClC-Ka (not shown). BSND mutations also cause sen-
sorineural deafness. The basolateral calcium-sensing receptor (CaSR) regulates ROMK and 
its overstimulation/gain of function causes an inhibition of ROMK, producing a Bartter-like 
phenotype. Calcium and magnesium are resorbed via paracellular channels, and any loss 
of the electrochemical driving force will lead to hypercalciuria and magnesium wasting. 
Dysfunction at this nephron segment leads to severe renal salt wasting, which activates the 
renin-angiotensin-aldosterone system. The increased delivery of salt to the cortical collecting 
duct promotes aldosterone dependant Na+ reabsorption via ENaC, which is coupled to K+ and 
H+ secretion, thus accounting for the hypokalaemic alkalosis seen.
Gitelman syndrome differs from Bartter syndrome due to the presence of hypocalciuria and 
does not typically manifest until adolescence or adulthood. Differentiating Gitelman syn-
drome from Type 3 Bartter syndrome can be difficult [20] due to expression of CLCKNB in 
distal nephron segments as well as the thick ascending limb of the loop of Henle.
Gitelman syndrome results from inactivating mutations in SLC12A3 which encodes the 
sodium chloride co-symporter (NCCT) (Figure 2) in the distal convoluted tubule [21]. The 
clinical phenotype can be variable and no phenotype-genotype correlation is yet understood. 
It is theorised that lack of correlation could be due to differences in function and/or expres-
sion of other basolateral chloride channels such as the voltage-gated chloride channel, KCl 
co-transporter or the cystic fibrosis transmembrane conductance regulator [22].
EAST syndrome (alias SeSAME, OMIM #612780) is causes by mutations in KCNJ10, a baso-
lateral potassium channel (Figure 2) expressed in the distal convoluted tubule [23, 24]. 
Biochemically, the phenotype exactly mimics Gitelman syndrome. Extra-renal manifestations 
of epilepsy, ataxia and speech dyspraxia make the syndrome recognisable.
The apically expressed thiazide sensitive co-transporter/sodium chloride co-transporter 
(NCCT) is shown. Mutations in Gitelman syndrome are associated with dysfunction in this 
channel, leading to salt wasting. Mutations in the basolateral potassium channel KCNJ10 
cause EAST syndrome and the serum biochemistry phenotypically mimics Gitelman syn-
drome. This channel is required for potassium recycling from the Na+–K+–ATPAse. Mutations 
in CLCNKB encoding the basolateral chloride channel ClC-Kb can also mimic Gitelman syn-
drome (as well as causing Bartter syndrome). Dysfunction of the apical magnesium channel 
in the distal convoluted tubule encoded by TRPM6 is seen in Gitelman syndrome, explaining 
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the hypomagnesaemia. Renal salt loss activates the renin-angiotensin-aldosterone system 
and increased delivery of salt to the cortical collecting duct promotes aldosterone dependant 
Na+ reabsorption via ENaC, which is coupled to K+ and H+ secretion, thus accounting for the 
hypokalaemic alkalosis seen.
Treatment for these in inherited salt wasting alkaloses conditions, in addition to electrolyte 
replacement, can comprise of NSAIDs, typically indomethacin. Renal production of PGE2 is 
typically elevated in response to reduced entry of chloride into the macula densa in the end 
of the thick ascending limb in these conditions [25]. Cyclooxygenase 2 expression is subse-
quently increased. PGE2 stimulates renin release by the juxtaglomerular apparatus contrib-
uting to the phenotype. PGE2 synthesis inhibition by NSAIDS will therefore reverse many 
of the clinical and biochemical abnormalities found in Bartter syndrome or phenotypically 
severe Gitelman syndrome (and EAST syndrome) [26].
4. Pendred Syndrome
Pendred syndrome is an autosomal recessive disorder resulting from biallelic mutations in 
SLC26A4 which encodes Pendrin, a multi-functional anion transporter. Pendrin acts a chloride/
bicarbonate exchanger in the cochlear, mediates iodide transport in the apical membrane of 
thyrocytes and as a chloride/bicarbonate exchanger in the apical membrane of beta- intercalated 
cells in the collecting duct (Figure 3). The resulting clinical picture is of sensorineural deafness, 
hypothyroidism, goitre and impaired bicarbonate secretion in states of metabolic alkalosis. 
Figure 2. The distal convoluted tubule and the transporters and channels associated with tubulopathies.
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Failure of the compensatory mechanisms in alkalotic states such as those triggered by diuretics, 
including thiazides, can result in a life threatening metabolic alkalosis [27].
Pendrin is expressed on the apical membranes of type B intercalated cells (shown) as well 
as and non-A, non-B intercalated cells (not shown). Mutations in SLC26A4, which encodes 
Pendrin, lead to a failure of the kidney to secrete a bicarbonate load, which is generated from 
intracellular carbonic anhydrase type 2, leading towards a metabolic alkalosis.
4.1. Glucocorticoid remedial Aldosteronism
Glucocorticoid remediable aldosteronism (GRA) is an autosomal dominant inherited cause 
of hypertension and is one of three known forms of familial hyperaldosteronism. Normally, 
aldosterone synthesis occurs in the zona glomerulosa of the adrenal gland which intentionally 
lacks the 17-hydroxylase enzyme to synthesise cortisol. In GRA, aldosterone is synthesised 
in the ACTH-sensitive zona fasciculata. In the zona glomerulosa, the gene CYP11B2 encodes 
aldosterone synthase which catalyses the conversion of deoxycorticosterone to corticosterone 
and 18-hydroxycorticosterone to aldosterone. In the zona fasciculata, CYP11B1, which encodes 
11β-hydroxylase, catalyses the conversion of 11-deoxycortisol to cortisol. In GRA, there is a 
chimeric gene duplication that results from unequal crossing over of CYP11B1 and CYP11B2 
resulting in ACTH-dependent activation of aldosterone synthase (rather than by the renin-
angiotensin-aldosterone system) which causes a significant increase in 18-oxocortisol and 
Figure 3. Pendrin expression in the intercalated cells of the kidney.
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18-hydroxycortisol. As this reaction occurs in the zona fasciculate, the aldosterone secretion 
is not sensitive to potassium loading as it would be in a normal subject due to the consistent 
prolonged release of ACTH. Consequentially, you do not always get hypokalaemia with this 
condition in contrast to subjects with other forms of hyperaldosteronism. Hypertension typi-
cally develops before the age of 21 and significant hypokalaemia develops following thiazide 
diuretic administration due to its effect on increased distal tubular sodium delivery to aldo-
sterone-sensitive potassium secretion site in the collecting duct. Although there is intra-family 
phenotypic variability with GRA, there is a strong prevalence of haemorrhagic stroke related to 
cerebral aneurysm which is even more prevalent than seen in autosomal dominant polycystic 
kidney disease [28, 29]. Subjects with GRA should subsequently have a cerebral MRA every 
5 years from puberty. Genetic testing is now preferred to a dexamethasone suppression test and 
demonstration of elevated 18-oxocortisol and 18-hydroxycortisol [30]. Treatment comprises of 
ACTH suppression with glucocorticoids with careful attention to the growth retardation effects 
of over-treatment in paediatric subjects. This will restore normotension and normokalaemia. 
Alternatively, mineralocorticoid receptor antagonists such as spironolactone may be used [31].
4.2. Congenital adrenal hyperplasia
Over 95% of patients with congenital adrenal hyperplasia have defective conversion of 
17-hydroxyprogesterone (17OHP) to 11-deoxycortisol. This is because of a mutation in the 
CYP21A2 gene which encodes the enzyme 21-hydroxylase which is responsible for this con-
version. CAH is an autosomal recessive disorder comprising two distinct types based on 
whether the condition is accompanied by salt wasting. Girls typically present with atypical 
genitalia (clitoral enlargement, urogenital sinus, labial fold fusion and genital orifice migra-
tion) but can present simply with severe salt wasting alone in the neonatal period. Boys typi-
cally present with severe salt wasting and do not manifest genital abnormalities until they 
reach an early onset puberty when they are toddlers. Phallic enlargement and hyperpigmen-
tation can occur. CAH is diagnosed when the serum 17-hydroxyprogesterone concentration 
is elevated. Adrenal ultrasound has additional diagnostic value in the neonatal period reveal-
ing a lobulated surface, adrenal limb length greater than 4 mm and abnormal echogenicity. 
A prenatal diagnosis can be made by molecular analysis of CYP21A2. Treatment involves a 
glucocorticoid such as hydrocortisone to replace cortisol deficiency and hyperandrogenaemia 
and subsequent fertility difficulties. Mineralocorticoid replacement such as fludrocortisone is 
necessary to reverse salt wasting and volume depletion and testicular US surveillance from 
adolescence due to an increased risk of testicular adrenal rest tumours [32, 33].
4.3. Apparent mineralocorticoid excess
Mineralocorticoid receptors in the collecting duct bind aldosterone and cortisol with similar 
affinity. Cortisol is normally converted into its inactive form cortisone by the enzyme 11-beta-
hydroxysteroid type 2 at sites of aldosterone activity to prevent competitive inhibition with 
aldosterone. In AME, a mutation in 11-beta-hydroxysteroid type 2 results in a reduction of 
cortisol conversion to cortisone and subsequently the mineralocorticoid receptor is activated 
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by excess cortisol. AME is autosomal recessive and causes severe hypertension in children 
in addition to hypercalciuria, nephrocalcinosis and renal failure due to an unknown mecha-
nism. Nephrogenic diabetes insipidus can also occur due to chronic hypokalaemia. Defects in 
HSD11B2 are responsible for this condition, some mutations result only in partial inhibition 
of 11-beta hydroxysteroid 2 resulting in a less severe phenotype. There is rough genotypic-
phenotypic correlation which includes the ratio of cortisol to cortisol metabolites which can 
be measured. Treatment for this condition aims at reducing endogenous cortisol production 
by dexamethasone or by blocking the mineralocorticoid receptor with spironolactone/eplere-
none. ENaC blockade has similar success with less side effects, so it is reasonable to instead 
use amiloride or triamterene especially in men. If hypercalciuria is present then it is reason-
able to use a thiazide to prevent nephrocalcinosis and subsequent renal impairment [34–36].
4.4. Liquorice ingestion and carbenoxolone
Liquorice (root of Glycyrrhiza glabra) is found in tobacco, snuff, foods, soft drinks, herbal med-
icine and teas in addition to its popular consumption as a confectionary item. Not all sweets 
contain the compound glycyrrhiza but instead are flavoured with alternative compounds to 
mimic liquorice so chronic ingestion should not cause the clinical picture of apparent miner-
alocorticoid excess. Glycyrrhiza inhibits 11-beta hydroxysteroid dehydrogenase which con-
verts cortisol to cortisone. Carbenoxolone, a liquorice-like compound has the same effect [37].
4.5. Liddle syndrome
Liddle syndrome is a rare autosomal dominant disorder associated with a gain of function 
mutation in the epithelial sodium channel (ENaC) situated on the luminal membrane of prin-
cipal cells in the collecting duct. In Liddle syndrome, ENaC function is increased which results 
in hypokalaemia and metabolic alkalosis. Increased activity of ENaC results in increased 
sodium reabsorption and potassium secretion and subsequent hypertension, hypokalaemia 
and metabolic alkalosis. Most patients present at a young age and not all have hypokalaemia 
but their potassium does run at lower range of normal.
Net sodium reabsorption occurs down a concentration gradient in principle cells via both 
ENaC on the luminal membrane and the Na–K–ATPase on the basolateral membrane. The 
greater net sodium reabsorption enhances potassium secretion through basolateral Na–K–
ATPase and subsequent open luminal potassium channels.
Mutations in SCNN1B and SCNN1G which encode the beta and gamma subunits of ENaC 
cause Liddle syndrome. When volume expansion occurs there is failure to remove ENaC 
channels from the luminal membrane under the influence of low renin and aldosterone and 
the phenotype mimics a hyperaldosteronism state yet plasma and urine aldosterone levels are 
in fact reduced. Treatment involves potassium paring diuretics which directly block ENaC 
such as Amiloride or Triamterene. Spironolactone, which competes with aldosterone to bind 
to the mineralocorticoid receptor, would not be effective as increased ENaC activity in not 
mediated by aldosterone [38, 39].
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4.6. Cortisol excess
Excess cortisol may allow stimulation of the mineralocorticoid receptor to leading to hyper-
tension and a hypokalemic metabolic alkalosis. Causes include excess exogenous admin-
istration of glucocorticoids such as hydrocortisone or secondary to endogenous cortisol 
hypersecretion either by Cushing’s syndrome or disease, ectopic ACTH production most 
commonly by small cell lung cancers or by a deoxycorticosterone-secreting tumour on the 
adrenal gland [2] (Figure 4).
Principal cells respond to a variety of stimuli to control Na+ and K+ transport. Aldosterone has 
the most pronounced effect. It acts through the mineralocorticoid receptor (MR) to increase 
surface expression of the epithelial sodium channel ENaC. Electrogenic Na+ reabsorption 
via ENaC is balanced by K+ secretion through ROMK and Cl− reabsorption through multiple 
pathways (not shown). The driving force that sets the electrochemical gradient for principal 
cell Na+ and K+ transport is the basolateral Na+–K+–ATPase.
5. Reasons to suspect and inherited cause of alkalosis
Clinical features of a metabolic alkalosis include muscle cramps, weakness, arrhythmias and 
seizures. Some of these signs and symptoms may be related to alterations in ionised calcium 
Figure 4. Salt transport in the principal cell.
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(increased pH causes plasma proteins to bind calcium more avidly, thus lowering ionised 
calcium concentration). The associated hypokalaemia may also give rise to many of these 
symptoms. Inherited forms of alkalosis are secondary to a heterogeneous group of renal 
tubulopathies. Typical manifestations range from asymptomatic biochemical disturbances to 
severe salt wasting leading in early life and may be complicated by renal failure. The impor-
tant clues to diagnosing an inherited cause of metabolic alkalosis include consistent electro-
lyte abnormalities (versus acquired changes in serum biochemistry), nephrocalcinosis, renal 
stone formation and renal impairment. Historical blood values are invaluable in this regard. 
A detailed family history is required to look for autosomal dominant and recessive patterns 
of disease. In children, failure to thrive, short stature, learning difficulties and rickets may also 
be evident. A history of early onset hypertension and a family history of stroke at a young 
age provides clues to look for inherited forms of hypertension including Liddle syndrome 
and GRA.
Individual syndromes may be distinguished by distinct biochemical profiles but modern day 
molecular genetics allows a more robust means to come to a firm diagnosis. A very similar bio-
chemical picture to Bartter and Gitelman syndromes can be induced by diuretic use or abuse, 
laxative abuse and chronic liquorice ingestion. However, urinary chloride will be raised in 
Bartter and Gitelman syndromes (>20 mmol/L) whereas vomiting, gastric drainage, diuret-
ics and post-hypercapnia will all have a low urinary chloride concentration (<10 mmol/L). 
Therefore, obtaining a careful drug and food history is important together with urine elec-
trolyte analysis and diuretic screening to make certain that the cause is not an acquired one. 
The optimal treatment of a metabolic alkalosis clearly depends on identifying the underlying 
cause. Treatment of life-threatening alkalosis may involve control of ventilation (sedation, 
intubation and controlled hypoventilation). Historically, administration of HCl or ammonium 
chloride/arginine chloride has been advocated. These are not advocated. Control of ventila-
tion and correction of volume status and improvement of renal haemodynamics is effective 
in cases of chloride loss. Haemodialysis may be used in extreme cases. Hypokalaemia should 
be corrected alongside the alkalosis. Treatment of Bartter and Gitelman syndrome, as detailed 
above, relies upon electrolyte replacement, attempts at disrupting the renal production of 
renin with NSAIDs and blocking the effects of excess mineralocorticoids with spironolactone, 
eplerenone and amiloride. Treatment of Liddle syndrome relies on sodium restriction and 
potassium-sparing diuretics which block ENaC and allow the correction of blood pressure, 
hypokalaemia and metabolic alkalosis.
6. Conclusions
A systemic metabolic alkalosis is an important electrolyte disturbance which can have signifi-
cant sequelae including neuromuscular irritability, tetany and cardiac rhythm disturbances. 
Hypokalaemia is a frequent accompanying electrolyte abnormality. Numerous inherited 
tubulopathies can cause this clinical and biochemical picture and acquired causes may mimic 
these. Molecular genetic testing allows a precise diagnosis and appropriate management to be 
given to patients with inherited salt wasting alkaloses.
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